Company: BIAF
Filing Date: 2025-04-15
Form Type: PRE 14A
Source: 0001641172-25-004857
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: PRE 14A
Chunk 2
---
 (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-2 to 1-for-25                                                                                                                                                                                                                                                                                            
 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and                                                                                                                                                                                                                                                                                                    
 included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment (the “Reverse                                                                                                                                                                                                                                                                          
 Stock Split Proposal”);                                                                                                                                                                                                                                                                                                                                                                                |
| (4) | To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 2,926,166 shares of our Common Stock upon the exercise of our Common Stock purchase warrants issued in connection with our private placement offering that closed on February 26, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Warrant Exercise Proposal”); |
| (5) | To approve a proposal to adjourn the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal or the Warrant Exercise Proposal (the “Adjournment Proposal”); and                                          |
| (6) | To transact such other business as may lawfully come before the meeting or any adjournment thereof.                                                                                                                                                                                                                                                                                                    |

Stockholders of record at the close of business on
April 8, 2025, are entitled to notice of and to vote at the Annual Meeting and any postponements or adjournments thereof. A list of stockholders
of record at the close of business on April 8, 2025, will be available for inspection by any stockholder for a period of ten days prior
to the Annual Meeting at our principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.

The Notice of Internet Availability of Proxy Materials
will be mailed to our stockholders on or about April [ ], 2025. If you previously requested electronic or paper delivery of the proxy
materials, you will be sent the proxy statement, the accompanying proxy card and our 2024 Annual Report to Stockholders, which is not
a part of our proxy solicitation materials, on or about April [ ], 2025. The Notice of Internet Availability of Proxy Materials contains
instructions on how to access an electronic copy of our proxy materials.

Your vote is very